Fucoidan from Spatoglossum schröederi promotes B16-F10 malignancy features modulation and antimelanoma in vivo activities

Bellan, D. L.; Bini, Israel Henrique; Santi, Fabiane de; Rossi, Gustavo Rodrigues; Biscaia, Stellee Marcela Petris; Junior, Atílio Máximo; Reis, Mariana Bisarro dos; Simas, Fernanda Fogagnoli; Oliveira, Cunha; Winnischofer, Sheila Maria Brochado; Leme, Daniela Morais; Chammas, Roger; Rocha, Hugo Alexandre Oliveira; Trindade, Edvaldo S.

doi:10.1016/j.algal.2023.103134

Cited by 3 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brown algae Spatoglossum spp. are well described as a source of compounds with many biological activities [15][16][17]; among them, Spatoglossum schröederi, a commonly brown seaweed found on the Brazilian coast, show antigenotoxic [18], antitumoral [19], anti-adhesive [20], antithrombotic [21], antigenotoxic [18], antinociceptive [22], anti-angiogenic [23], antiparasitic [24], and nutraceutical [25] effects. Despite the variety of studies that characterize this seaweed as a source of many compounds with potential pharmacological activities, there is a lack of knowledge and prospective studies about its anti-inflammatory potential.…”

Section: Introductionmentioning

confidence: 99%

Anti-Inflammatory Activity of Fucan from Spatoglossum schröederi in a Murine Model of Generalized Inflammation Induced by Zymosan

Silva,

Souza,

Silva

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Fucans from marine algae have been the object of many studies that demonstrated a broad spectrum of biological activities, including anti-inflammatory effects. The aim of this study was to verify the protective effects of a fucan extracted from the brown algae Spatoglossum schröederi in animals submitted to a generalized inflammation model induced by zymosan (ZIGI). BALB/c mice were first submitted to zymosan-induced peritonitis to evaluate the treatment dose capable of inhibiting the induced cellular migration in a simple model of inflammation. Mice were treated by the intravenous route with three doses (20, 10, and 5 mg/kg) of our fucan and, 1 h later, were inoculated with an intraperitoneal dose of zymosan (40 mg/kg). Peritoneal exudate was collected 24 h later for the evaluation of leukocyte migration. Doses of the fucan of Spatoglossum schröederi at 20 and 10 mg/kg reduced peritoneal cellular migration and were selected to perform ZIGI experiments. In the ZIGI model, treatment was administered 1 h before and 6 h after the zymosan inoculation (500 mg/kg). Treatments and challenges were administered via intravenous and intraperitoneal routes, respectively. Systemic toxicity was assessed 6 h after inoculation, based on three clinical signs (bristly hair, prostration, and diarrhea). The peritoneal exudate was collected to assess cellular migration and IL-6 levels, while blood samples were collected to determine IL-6, ALT, and AST levels. Liver tissue was collected for histopathological analysis. In another experimental series, weight loss was evaluated for 15 days after zymosan inoculation and fucan treatment. The fucan treatment did not present any effect on ZIGI systemic toxicity; however, a fucan dose of 20 mg/kg was capable of reducing the weight loss in treated mice. The treatment with both doses also reduced the cellular migration and reduced IL-6 levels in peritoneal exudate and serum in doses of 20 and 10 mg/kg, respectively. They also presented a protective effect in the liver, with a reduction in hepatic transaminase levels in both doses of treatment and attenuated histological damage in the liver at a dose of 10 mg/kg. Fucan from S. schröederi presented a promising pharmacological activity upon the murine model of ZIGI, with potential anti-inflammatory and hepatic protective effects, and should be the target of profound and elucidative studies.

show abstract